Zhou Lirun, Bao Lei, Wang Yaxin, Chen Mengping, Zhang Yingying, Geng Zihan, Zhao Ronghua, Sun Jing, Bao Yanyan, Shi Yujing, Yao Rongmei, Guo Shanshan, Cui Xiaolan
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Front Pharmacol. 2021 Nov 19;12:755796. doi: 10.3389/fphar.2021.755796. eCollection 2021.
Geniposide, an iridoid glycoside purified from the fruit of , has been reported to possess pleiotropic activity against different diseases. In particular, geniposide possesses a variety of biological activities and exerts good therapeutic effects in the treatment of several strains of the influenza virus. However, the molecular mechanism for the therapeutic effect has not been well defined. This study aimed to investigate the mechanism of geniposide on influenza A virus (IAV). The potential targets and signaling pathways of geniposide in the IAV infection were predicted using network pharmacology analysis. According to the result of network pharmacology analysis, we validated the calcium signaling pathway induced by IAV and investigated the effect of geniposide extracted from on this pathway. The primary Gene Ontology (GO) biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways KEGG enrichment analysis indicated that geniposide has a multi-target and multi-pathway inhibitory effect against influenza, and one of the mechanisms involves calcium signaling pathway. In the current study, geniposide treatment greatly decreased the levels of RNA polymerase in HEK-293T cells infected with IAV. Knocking down CAMKII in IAV-infected HEK-293T cells enhanced virus RNA (vRNA) production. Geniposide treatment increased CAMKII expression after IAV infection. Meanwhile, the CREB and c-Fos expressions were inhibited by geniposide after IAV infection. The experimental validation data showed that the geniposide was able to alleviate extracellular Ca influx, dramatically decreased neuraminidase activity, and suppressed IAV replication regulating the calcium signaling pathway. These anti-IAV effects might be related to the disrupted interplay between IAV RNA polymerase and CAMKII and the regulation of the downstream calcium signaling pathway essential for IAV replication. Taken together, the findings reveal a new facet of the mechanism by which geniposide fights IAV in a way that depends on CAMKII replication.
京尼平苷是从栀子果实中纯化得到的一种环烯醚萜苷,据报道它对多种疾病具有多效活性。特别是,京尼平苷具有多种生物活性,在治疗多种流感病毒株方面发挥着良好的治疗作用。然而,其治疗效果的分子机制尚未完全明确。本研究旨在探讨京尼平苷对甲型流感病毒(IAV)的作用机制。利用网络药理学分析预测了京尼平苷在IAV感染中的潜在靶点和信号通路。根据网络药理学分析结果,我们验证了IAV诱导的钙信号通路,并研究了从栀子中提取的京尼平苷对该通路的影响。初步的基因本体(GO)生物学过程和京都基因与基因组百科全书(KEGG)通路KEGG富集分析表明,京尼平苷对流感具有多靶点和多通路抑制作用,其中一种机制涉及钙信号通路。在本研究中,京尼平苷处理显著降低了感染IAV的HEK-293T细胞中RNA聚合酶的水平。在感染IAV的HEK-293T细胞中敲低钙/钙调蛋白依赖性蛋白激酶II(CAMKII)可增强病毒RNA(vRNA)的产生。京尼平苷处理在IAV感染后增加了CAMKII的表达。同时,京尼平苷在IAV感染后抑制了CREB和c-Fos的表达。实验验证数据表明,京尼平苷能够减轻细胞外Ca内流,显著降低神经氨酸酶活性,并通过调节钙信号通路抑制IAV复制。这些抗IAV作用可能与IAV RNA聚合酶和CAMKII之间相互作用的破坏以及对IAV复制所必需的下游钙信号通路的调节有关。综上所述,这些发现揭示了京尼平苷通过依赖CAMKII复制的方式对抗IAV机制的一个新方面。